Literature DB >> 10395100

Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.

F L Fierens1, P M Vanderheyden, J P De Backer, G Vauquelin.   

Abstract

Angiotensin II increased the inositol phosphates production (EC50 = 3.4+/-0.7 nM) in Chinese hamster ovary (CHO) cells expressing the cloned human angiotensin AT1 receptor (CHO-AT1 cells). Coincubation with angiotensin AT1 receptor antagonists produced parallel rightward shifts of the concentration-response curve without affecting the maximal response. The potency order is 2-ethoxy-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benz imidazoline-7-carboxylic acid (candesartan) > 2-n-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]i midazole-5-carboxylic acid (EXP3174) > 2-n-butyl-4-spirocyclopentane-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]2-imidazolin-5-one (irbesartan)> of 2-n-butyl-4-chloro-5-hydroxymethyl-1-(2'-(1H-tetrazol-5-yl)bipheny l-4-yl)methyl]imidazole (losartan). Additionally, preincubation with these antagonists depressed the maximal response, i.e., 95%, 70%, 30% of the control response for candesartan, EXP3174 and irbesartan and not detectable for losartan. Increasing the antagonist concentration or prolonging the preincubation time did not affect this depression. Furthermore, these values remained constant for candesartan and EXP3174, when the angiotensin II incubation time varied between 1 and 5 min. Our data indicate that antagonist-receptor complexes are divided into a fast reversible/surmountable population and a tight binding/insurmountable population at the very onset of the incubation with angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395100     DOI: 10.1016/s0014-2999(99)00205-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

3.  CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.

Authors:  Xiumei Hong; Shanchun Zhang; Guangyun Mao; Shanqun Jiang; Yan Zhang; Yunxian Yu; Genfu Tang; Houxun Xing; Xiping Xu
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

4.  Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.

Authors:  P M Vanderheyden; I Verheijen; F L Fierens; J P DeBacker; G Vauquelin
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

5.  A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.

Authors:  David C Swinney; Paul Beavis; Kai-Ting Chuang; Yue Zheng; Ina Lee; Peter Gee; Jerome Deval; David M Rotstein; Marianna Dioszegi; Palani Ravendran; Jun Zhang; Surya Sankuratri; Rama Kondru; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 6.  Irbesartan: an updated review of its use in cardiovascular disorders.

Authors:  A Markham; C M Spencer; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

7.  The non-biphenyl-tetrazole angiotensin AT1 receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT1 receptor.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

Review 8.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

9.  Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

Authors:  M T Le; M K Pugsley; G Vauquelin; I Van Liefde
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 10.  Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.

Authors:  Gustav G Belz
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.